2021
DOI: 10.3389/fimmu.2021.613502
|View full text |Cite
|
Sign up to set email alerts
|

Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery

Abstract: In these times of COVID-19 pandemic, concern has been raised about the potential effects of SARS-CoV-2 infection on immunocompromised patients, particularly on those receiving B-cell depleting agents and having therefore a severely depressed humoral response. Convalescent plasma can be a therapeutic option for these patients. Understanding the underlying mechanisms of convalescent plasma is crucial to optimize such therapeutic approach. Here, we describe a COVID-19 patient who was deeply immunosuppressed follo… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(8 citation statements)
references
References 33 publications
0
8
0
Order By: Relevance
“…The duration of viral shedding after the onset of COVID-19 is usually 20 days [ 3 ]. However, immunocompromised patients with hematologic malignancies, those undergoing chemotherapy, and especially those treated with BR, have reportedly shed the active virus for longer periods [ [5] , [6] , [7] , [8] ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The duration of viral shedding after the onset of COVID-19 is usually 20 days [ 3 ]. However, immunocompromised patients with hematologic malignancies, those undergoing chemotherapy, and especially those treated with BR, have reportedly shed the active virus for longer periods [ [5] , [6] , [7] , [8] ].…”
Section: Discussionmentioning
confidence: 99%
“…Ref, reference; M, male; F, female; FL, follicular lymphoma; MCL, myeloid cell leukemia; WM/LPL, Waldenström macroglobulinemia/LPL; CLL, chronic lymphocytic leukemia; NA, not available; C, ciclesonide; F, favipiravir; H, hyperimmune plasma infusion; D, dexamethasone; R, remdesivir. Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 age/sex 47 M NA NA 62F 74 M 71 M underlying disease FL MCL WM/LPL FL CLL FL Status CR NA NA CR CR CR last BR therapy before COVID-19 4 months 17 days 8 days NA 5 months 9 months duration of PCR positive for SARS-CoV-2 59 days 42 days 56 days 66 days 111 days above 8 weeks treatment for COVID-19 C, F NA NA H, D, R H, D D, R Outcome cure death cure Cure cure cure References [ 5 ] [ 6 ] [ 6 ] [ 7 ] [ 8 ] This case …”
Section: Discussionmentioning
confidence: 99%
“…Convalescent plasma was collected from 32 male donors (CP), who had fully recovered for at least 28 days after COVID-19 onset and presented an anti-S protein-specific IgG response, ranging from 29.4-135.6 ratio, with an average ratio of 79 using an in-house developed Luminex assay (42), correlating to neutralizing titers (43, 44). Due to the difficulties to obtain high-titer plasma from convalescent donors, we collected from March, 1 st , 2021 onwards, plasma from 24 non-COVID-19 male donors (VP), who had received their second dose of an mRNA-based vaccine (Moderna or Pfizer) and exhibited an anti-S protein IgG response ranging from 73.3-143.7.6 ratio, with an average ratio of 118 by Luminex.…”
Section: Methodsmentioning
confidence: 99%
“…In the largest case series to date, Hueso et al treated 17 patients with B-cell depletion and prolonged COVID-19 (median of 56 days since symptom onset) with convalescent plasma, resulting in improvement in symptoms and laboratory parameters in 16 out of 17 patients [12] . Similarly, Zimmerli et al and Jassem et al both successfully treated two patients with B-cell depletion due to hematologic malignancies with convalescent plasma [18] , [19] . More recently, several groups have reported successful treatment of such patients with mAbs [15] , [16] , [17] , [20] .…”
Section: Discussionmentioning
confidence: 96%